Elevance Health Inc.
(NYSE:ELV) on Wednesday reported second-quarter results that topped Wall Street estimates and raised its full-year adjusted earnings and operating cash flow guidance, supported by higher premium yields and continued growth in its Carelon business.
Adjusted earnings came in at $7.45 per share, beating the analyst consensus estimate of $6.21.
Revenue rose to $49.83 billion, above the consensus estimate of $48.69 billion.
Premium Yields, Carelon Support Growth Revenue increased by $400 million from a year earlier, driven by higher premium yields in the Health Benefits segment and stronger CarelonRx product revenue.
